Show simple item record

dc.contributor.authorCamidge, R
dc.contributor.authorKim, HR
dc.contributor.authorAhn, MJ
dc.contributor.authorYang, JCH
dc.contributor.authorHan, JY
dc.contributor.authorHochmair, MJ
dc.contributor.authorLee, KH
dc.contributor.authorDelmonte, A
dc.contributor.authorCampelo, MRG
dc.contributor.authorKim, DW
dc.contributor.authorGriesinger, F
dc.contributor.authorFelip, E
dc.contributor.authorCalifano, Raffaele
dc.contributor.authorSpira, A
dc.contributor.authorGettinger, S
dc.contributor.authorTiseo, M
dc.contributor.authorNi, Q
dc.contributor.authorZhang, P
dc.contributor.authorPopat, S
dc.date.accessioned2020-01-29T15:17:52Z
dc.date.available2020-01-29T15:17:52Z
dc.date.issued2019en
dc.identifier.citationCamidge R, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial. Annals of Oncology. 2019;30:ix195-ix6.en
dc.identifier.doi10.1093/annonc/mdz446en
dc.identifier.urihttp://hdl.handle.net/10541/622694
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdz446en
dc.titleBrigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK1 NSCLC: Updated results from the phase III ALTA-1L trialen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMedical Oncology, University of Colorado Cancer Center, 80045 - Aurora/USen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record